Alnylam's stock is down 30% despite a booming biotech market. Here's why
Alnylam is one of biopharma’s biggest mysteries so far in 2026. The broader market is seeing a resurgence after years of a bearish environment. M&A is up, IPOs are back with record-breaking force and the ...
read at Endpoints ↗Neutral
July 28, 2026 10:00 AM EDT Pharma Alnylam's stock is down 30% despite a booming biotech market. Here's why. Max Gelman Senior Editor Alnylam is one of biopharma’s biggest mysteries so far in 2026.
The broader market is seeing a resurgence after years of a bearish environment. M&A … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that